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Abstract 
The development of blood cells has long served as a model system to study the generation of 
diverse mature cells from multipotent progenitors.  The article by Org et al (2015, this issue) 
reveals how transcription factor competition on primed DNA templates may contribute to 
embryonic blood cell specification during the early stages of mesoderm development.  The 
study not only provides new insights into the functionality of the key haematopoietic 
transcription factor Scl/Tal1, but also provides a potentially widely applicable framework for 
transcription factor-mediated cell fate specification. 
 
Main Text 
The development of cells with distinct tissue identities from multipotent embryonic 
progenitor cells represents a hallmark of all multicellular organisms.  Since different tissue 
identities are to a large extent mediated by tissue specific gene expression patterns, 
transcription factor (TF) proteins responsible for establishing tissue-specific expression 
profiles have long been recognised as key regulators of early tissue development.  
Nevertheless, much remains to be learned about the molecular mechanisms by which a given 
TF can promote one fate over others within multipotent progenitor cells, and thus determine 
which mature tissue a given cel will differentiate into.  
 
Org et al (Org et al, 2015) in this issue of the EMBO Journal investigated this question by 
studying the basic helix-loop-helix TF Scl, also known as Tal1.  The Scl gene was originally 
discovered through its involvement in recurrent chromosome translocations in T-cell acute 
lymphoblastic leukaemia.  Translocations cause ectopic expression of Scl in T-cells, which 
was subsequently shown in mouse models to constitute a leukaemia initiating event (for 
review see (Begley & Green, 1999)).  Scl’s reputation as the master regulator of blood cell 
development was established when a series of papers reported that Scl is essential for the 
development of all blood lineages during early development (Porcher et al, 1996; Robb et al, 
1996; Robb et al, 1995; Shivdasani et al, 1995).  Developmental haematopoiesis occurs in 
multiple waves, first producing primitive red blood cells, followed by multipotent blood 
progenitor and finally pluripotent haematopoietic stem cells.  With the exception of the first 
wave of primitive erythropoiesis where acquisition of blood fate by early mesodermal cells 
may occur very rapidly (Padrón-Barthe et al, 2014), fate restriction of early mesodermal cells 
towards a haematopoietic identity for all subsequent waves is thought to occur in a stepwise 
fashion, where cells progressively loose the potential to form cardiac muscle, smooth muscle 
and endothelium (Ciau-Uitz et al, 2014).  During this process, cells transit through 
intermediate haemangioblast and hemogenic endothelial cell stages, and Scl has been shown 
to be required for the transition to hemogenic endothelium (Figure 1A) (Lancrin et al, 2009).  
Since Scl is required for the development of blood cells produced by all waves of early 
haematopoiesis, Scl stands out as being critically important for the acquisition of a 
haematopoietic fate by any early mesodermal cell.   
 
Following up on initial observations in Scl-/- embryonic stem cells (ESCs) (Ismailoglu et al, 
2008), the Mikkola group showed in 2012 that deletion of Scl not only abrogates all 
haematopoietic development, but also increases the numbers of cells that will acquire 
alternative early mesodermal fates, in particular cardiac muscle (Van Handel et al, 2012).  
The new study by Org et al builds on these observations, by addressing two key questions 
about Scl function during early mesodermal fate specification: (i) how does Scl promote 
haematopoietic fates, and (ii) how does Scl inhibit cardiomyocyte differentiation.  Using a 
combination of genome-scale approaches, Org et al (Org et al, 2015) integrated genome-wide 
maps of Scl binding in ESC-derived mesodermal cells with gene expression profiling, 
genome-wide profiles of histone modification status, genome-wide maps of the bHLH TF 
Hand1 known to promote cardiac development, and also genome-wide maps for members of 
the GATA family of TFs known to be involved in either blood or cardiac development.  
Importantly, analysis of wild-type cells was complemented with key experiments performed 
in cells derived from TF knock-out ESCs.  The comprehensive new datasets reported by Org 
et al (Org et al, 2015) represent a very valuable new resource for the wider haematopoiesis 
research community.  Moreover, the comparative and integrated analysis performed by the 
authors provides a number of important new insights, which include: (a) Scl appears to 
influence mesoderm diversification largely through binding to both haematopoietic and 
cardiac enhancers, (b) repression of the cardiac fate by Scl appears to be the consequence of 
blocking the binding of cardiac-promoting TFs to the same sites, with decommissioning of 
cardiac enhancers during the ensuing blood differentiation being accompanied by the removal 
of activating histone marks, (c) Scl does not appear to act as a pioneer factor that opens up 
chromatin, but instead exploits a pre-configured epigenetic landscape, and (d) haematopoietic 
Gata TFs can bind together with Scl to both cardiac and haematopoietic enhancers, and 
critically contribute to activating the haematopoietic elements whereas they are apparently 
dispensable for the repression of the cardiac enhancers.   
 
While the set of conclusions listed above provides important new insights into cell fate 
control during early mesodermal development (see Figure 1B), what makes the paper by Org 
et al (Org et al, 2015) even more exciting is that it poses a number of intriguing questions for 
future investigation.  For example, if Scl does not function as a pioneer factor, what is the 
identity of the TFs that open up the chromatin template for subsequent Scl binding?  Related 
to this point, Porcher et al (Porcher et al, 1999) showed in 1999 that the DNA binding domain 
of Scl is not required for its early role in blood specification, but then becomes important 
later during development for the maturation of red blood cells.  This observation could be 
interpreted to mean that Scl may function as a pioneer factor during these later stages of red 
blood cell development, since binding to DNA seems to require Scl’s own DNA binding 
domain rather than being mediated by collaborating TFs.  Org et al (Org et al, 2015) also 
reinforce the notion that Scl binding profiles differ greatly when analysed in different cellular 
contexts (Beck et al, 2013; Kassouf et al, 2010; Palii et al, 2011; Tijssen et al, 2011; Wilson 
et al, 2009; Wu et al, 2014).  Importantly, previous studies identified TFs that may play a role 
in establishing cell-type specific binding profiles of Scl (Calero-Nieto et al, 2014; Lichtinger 
et al, 2012).  To fully understand Scl’s earliest function during mesoderm diversification, it 
will be critical to identify such TFs for these early stages.  It may turn out that these are the 
very same TFs mentioned above when discussing the need to identify the factors that 
establish the chromatin template for Scl binding.   
Lastly, with Scl blocking Hand1 binding to cardiac enhancers and thereby inhibiting 
mesoderm differentiation into cardiac cells, is there a reciprocal inhibition of blood 
development by Hand1 (or some other bHLH factor), by means of blocking the binding of 
Scl to haematopoietic enhancers?  And if such reciprocal blocking were to be a widespread 
phenomenon in early multipotent cells, what are the specific mechanisms that will cause 
resolution of cellular fates down just one of the alternative outcomes?  A complex interplay 
of external (signalling) and internal (TF network execution) processes is likely to be 
responsible, and it is difficult to see how some of the key questions will be resolved without 
taking molecular analysis down to the single cell level.  Single cell profiling of both ESC and 
embryo-derived early blood-fated mesodermal cells has recently been reported (Moignard et 
al, 2015; Wilkinson et al, 2014).  Such approaches have the potential to identify and 
characterise the nature of those, potentially rare, cells that co-express lineage-determining 
TFs such as Scl and Hand1 during early development.  Time-lapse imaging approaches at 
single cell resolution represent another key tool that will likely be essential to resolve the 
mechanisms underlying fate resolution of early multipotential cells.  However, their 
adaptation from previous ESC based experiments (Eilken et al, 2009) to whole embryo 
analysis is likely to require overcoming significant technical challenges, both in terms of 
embryo in vitro culture protocols and image analysis of dynamic 3-dimensional objects at 
single cell resolution.  Importantly, in addition to advancing our understanding of 
fundamental biological processes involved in cell fate control, a better understanding of 
blood and cardiac development has substantial “translational” implications, in the short term 
probably most likely in relation to the generation of more accurate in vitro models of human 
disease, but in the longer term also in relation to the development of cell-based therapies for 
regenerative medicine applications.   
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Figure 1: A) Development of blood cells from early mesoderm.  Shown are the 
lineage relationships between early cardiac, endothelial and blood 
development, together with haemangioblast and hemogenic endothelial 
intermediate stages.  B) Model illustrating the generation of diverse cell fates 
through transcription factor competition on enhancer elements.  Enhancers are 
opened up (primed), which is followed by competitive binding of transcription 
factors promoting alternative fates.  During this process, multipotent cells 
gradually loose their potential, and become increasingly specified to a 
particular lineage.    
